Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-24T03:55:33.759Z Has data issue: false hasContentIssue false
  • English
  • Français

Clozapine for the treatment of levodopa-induced psychosis and dyskinesia in Parkinson's disease

Published online by Cambridge University Press:  13 June 2014

TA Hughes ,
RHS Mindham  and
HF Ross
TA Hughes
Affiliation:
Division of Psychiatry and Behavioural Sciences, School of Medicine, University of Leeds, 15 Hyde Terrace, Leeds LS2 9LT, England
RHS Mindham
Affiliation:
Division of Psychiatry and Behavioural Sciences, School of Medicine, University of Leeds, 15 Hyde Terrace, Leeds LS2 9LT, England
HF Ross
Affiliation:
Division of Psychiatry and Behavioural Sciences, School of Medicine, University of Leeds, 15 Hyde Terrace, Leeds LS2 9LT, England
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Information
Irish Journal of Psychological Medicine , Volume 12 , Issue 1 , March 1995 , pp. 39
Copyright
Copyright © Cambridge University Press 1995

References

1.Jalaenques, L, Coudert, AJ. Clozapine for the treatment of levodopa induced psychosis and dyskinesia in Parkinson's disease. Ir J Psychol Med. 1994; 11:83–88.CrossRefGoogle Scholar
2.ABPI Data Sheet Compendium. Datapharm Publications Limited, 1994-1995; 1377.Google Scholar
3.British National Formulary. British Medical Association and Royal Pharmaceutical Association of Great Britain. 1994; 150.Google Scholar